Thyroid Cancer

Lori J Wirth, ASCO 2018 – Treatment Approaches and Advances in Thyroid Cancer Research

touchONCOLOGY meets with Lori J Wirth from Harvard Medical School and Massachusetts General Hospital in Boston, MA to discuss important treatment approaches and advances for thyroid cancer, including investigating lenvatinib and major findings of the SELECT trial, and how the clinical development of new therapies such as LOXO-292 and spartalizumab may contribute to treatment paradigms […]

Can We Improve Thyroid Fine-needle Aspiration Cytology Adequacy in a Low-volume Thyroid Center?

Oncology & Hematology Review, 2017;13(1):21-4 DOI: https://doi.org/10.17925/OHR.2017.13.01.21

Thyroid cancer is the most common endocrine malignancy, and has increased in incidence in recent decades.1–3 Fine-needle aspiration cytology (FNAC) is the mainstay of assessment of thyroid nodules and diagnosis of malignancy.4,5 Several reports have suggested that ultrasound (US)-guided FNAC has many advantages over palpation-guided biopsy. It is now generally recommended that thyroid nodules should […]

Can We Improve Thyroid Fine-needle Aspiration Cytology Adequacy in a Low-volume Thyroid Center?

Oncology & Hematology Review, 2017;13(1): Epub ahead of print

Thyroid cancer is the most common endocrine malignancy, and has increased in incidence in recent decades.1–3 Fine-needle aspiration cytology (FNAC) is the mainstay of assessment of thyroid nodules and diagnosis of malignancy.4,5 Several reports have suggested that ultrasound (US) -guided FNAC has many advantages over palpation-guided biopsy. It is now generally recommended that thyroid nodules […]

ESMO 2016 Lars Bastholt Interview

  Dr Lars Bastholt discusses lenvatinib for the treatment of differentiated thyroid cancer. FILMED AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING, OCTOBER 2016.

Tumour Lysis Syndrome in Solid Tumours Associated with Tyrosine Kinase Inhibitors – A Case Illustrated Review

European Oncology & Haematology, 2016;12(1):51–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.51

Tyrosine kinase inhibitors (TKIs) are small anticancer molecules targeting protooncogenic tyrosine kinase signalling pathways.1 TKIs are now therapies used routinely in the treatment of many solid tumours such as gastrointestinal stromal tumour (GIST), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer, breast cancer and non-small-cell lung carcinoma (Table 1). As opposed to cytotoxic […]

Efficacy/Safety of Lenvatinib for the treatment of pts w/ 131I-refractory thyroid cancer

ASCO 2015: Matthew Taylor, MD discusses efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.

Treament for Follicular Thyroid Cancer

UW Health’s Dr. David Schneider explains the treatment options for patients with Follicular Thyroid Cancer.

Thyroid Tumor Marker

Living With Thyroid Cancer: Thyroid Tumor Marker.

Targeted therapy for iodine-refractory thyroid cancer

Dr Tahara (National Cancer Center Hospital East, Kashiwa, Japan) talks to ecancertv at ESMO 2014 about the development of a new targeted therapy for the treatment of iodine-refractory thyroid cancer.